ANNOVIS BIO (ANVS)
US03615A1088 - Common Stock
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
ANVS Stock Earnings: Annovis Bio Beats EPS for Q1 2024
ANVS stock results show that Annovis Bio beat analyst estimates for earnings per share the first quarter of 2024.
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results.
What's going on in today's session
Top movers analysis one hour before the close of the markets on 2024-05-09: top gainers and losers in today's session.
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company...
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
MALVERN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company...
Unusual volume stocks are being observed in Wednesday's session.
The trading volume of these stocks is deviating from the norm in today's session.
What's going on in today's session
Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
In today's session, these stocks are experiencing unusual volume.
Discover the stocks with unexpected trading volume in today's session on the US markets.
Which stocks are moving on Tuesday?
Which stocks are experiencing notable movement on Tuesday?
Which stocks are experiencing notable movement on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
These stocks are gapping in today's session
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition...
ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023
ANVS stock results show that Annovis Bio missed analyst estimates for earnings per share the fourth quarter of 2023.
ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Annovis Bio (NYSE:ANVS) just reported results for the fourth quarter of 2023.An...
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company...
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:...
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for...
Sell Signal: 3 Stocks to Unload Before the Bubble Bursts
It's time to offload stocks in the automotive, aerospace, and biotech sectors due to emerging financial and operational risks.
Annovis Bio falls after Brookline Capital downgrades on PD trial complications (NYSE:ANVS)
Orbon Alija/E+ via Getty Images Annovis Bio (NYSE:ANVS) shares fell in early trade on Wednesday after Brookline Capital Markets downgraded the company’s...
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for...
3 Growth Stocks to Sell in February Before They Bottom
Discover why these growth stocks to sell are facing adversities in automotive retail, aerospace, defense and biotechnology.
Annovis Bio files for $250M mixed shelf (NYSE:ANVS)
Annovis Bio files prospectus for a proposed mixed shelf offering of up to $250M, as per SEC filing.
Annovis falls 16% on Phase 3 data delay for Parkinson's drug (NYSE:ANVS)
Shares of Annovis Bio (ANVS) tumbled 16% in morning trading Wednesday after the company said the release of Phase 3 data for its Parkinson’s disease drug candid